The results of joint research with Dr. Noriyuki Azuma, Dr. Hiroshi Nishina, and colleagues at Tokyo Medical and Dental University and the National Center for Child Health and Development have been published in Human Molecular Genetics, an international journal of human genetics. This research focused on INTS15, a protein of unknown function that was speculated […]

A review article summarizing research results from the discovery of thalidomide’s intracellular target cereblon (CRBN) to the latest research results has been published in Chemical Society Reviews (IF=60.615). The first author of the article is Assistant Professor Yamamoto, co-authored with Dr. Handa and Dr. Ito of Tokyo Medical University. https://pubs.rsc.org/en/content/articlepdf/2022/CS/D2CS00116K

The results of joint research with Professor Handa and Associate Professor Ito of Tokyo Medical University were published in the open access journal Communications Biology on November 11. This is the finding that pomalidomide, a small molecule compound used as a treatment for multiple myeloma, causes selective degradation of the disease-related protein PLZF, suggesting that

A review article summarizing the latest basic research and drug development related to CRBN, from the discovery of thalidomide’s intracellular target cereblon (CRBN) to drug discovery and development, has been published in Cell Chemical Biology.

The results of our joint research with Associate Professor Okuda and Professor Nishimura at Yokohama City University were published in Nucleic Acids Research on July 16. Mr. Suwa, a graduate student, is the co-first author. This is the first study to show that a naturally degenerate region common to three types of RNA polymerases interacts

The results of joint research with Professor Hidetaka Takahashi and Assistant Professor Hidefumi Suzuki at Yokohama City University were published in Nature Communications on May 25. This work shows that the Mediator complex of transcription is involved in the transient arrest of Pol II at the 3′ end of replication-dependent histone genes.

The results of a collaborative study with Professor Hiroshi Handa of Tokyo Medical University and Professor Masahiro Kizaki of Saitama Medical University were published in Nature Chemical Biology on September 21. The study revealed that the degradation of a protein called ARID2 is involved in the anticancer effect of pomalidomide, a drug for multiple myeloma,

The results of our joint research with Prof. Handa and colleagues at Tokyo Medical University have been published in Scientific Reports. This is the result of a genetic screening to elucidate the mechanism of anticancer activity of thalidomide derivatives against multiple myeloma, and revealed that the subcellular localization of thalidomide target protein cereblon (CRBN) plays